Do hepatitis B virus and hepatitis C virus co-infections increase hepatocellular carcinoma occurrence through synergistically modulating lipogenic gene expression?

Hepatology Research

Volumn 42, Issue 8, 2012, Pages 733-740

  Wu, Qi ^a   Liu, Qiang ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Hepatitis B virus and hepatitis C virus co infection and hepatocellular carcinoma; Peroxisome proliferator activated receptors; PI3K PTEN Akt signaling pathway; Steatosis; Sterol regulatory element binding proteins; Unfolded protein response

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; FAS ANTIGEN; HEPATITIS B VIRUS X PROTEIN; INTERFERON; LIVER X RECEPTOR; NONSTRUCTURAL PROTEIN 5A; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

AGE; ARTICLE; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; DISEASE ASSOCIATION; GENE EXPRESSION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIPID METABOLISM; LIPOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MIXED INFECTION; NONHUMAN; OBESITY; PRIORITY JOURNAL; SCID MOUSE; SEX DIFFERENCE; SEXUAL TRANSMISSION; STEATOSIS; VERTICAL TRANSMISSION;

EID: 84863754065     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2012.00994.x     Document Type: Article

References (83)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007 (Jun); 132 (7): 2557-76.
2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006 (Oct); 45 (4): 529-38.
3. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004 (Mar); 11 (2): 97-107.
4. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999 (Jan); 6 (1): 35-47.
5. Chu CJ, Lee SD. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol 2008 (Apr); 23 (4): 512-20.
6. Liu Z, Hou J. Hepatitis B virus (HBV) and hepatitis C virus (HCV) dual infection. Int J Med Sci 2006; 3 (2): 57-62.
7. Pallas JR, Farinas-Alvarez C, Prieto D, Delgado-Rodriguez M. Coinfections by HIV, hepatitis B and hepatitis C in imprisoned injecting drug users. Eur J Epidemiol 1999 (Sep); 15 (8): 699-704.
8. Reddy GA, Dakshinamurthy KV, Neelaprasad P, Gangadhar T, Lakshmi V. Prevalence of HBV and HCV dual infection in patients on haemodialysis. Indian J Med Microbiol 2005 (Jan); 23 (1): 41-3.
9. Aroldi A, Lampertico P, Montagnino G etal. Natural history of hepatitis B and C in renal allograft recipients. Transplantation 2005 (May 15); 79 (9): 1132-6.
10. Irshad M, Peter S. Spectrum of viral hepatitis in thalassemic children receiving multiple blood transfusions. Indian J Gastroenterol 2002 (Sep); 21 (5): 183-4.
11. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007 (Oct); 7 (10): 763-77.
12. Kuhajda FP. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 2006 (Jun 15); 66 (12): 5977-80.
13. Yahagi N, Shimano H, Hasegawa K etal. Co-ordinate activation of lipogenic enzymes in hepatocellular carcinoma. Eur J Cancer 2005 (Jun); 41 (9): 1316-22.
14. Shiffman ML. Management of acute hepatitis B. Clin Liver Dis 2010 (Feb); 14 (1): 75-91.
15. Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010 (Feb); 14 (1): 1-21, vii.
16. Nelson PK, Mathers BM, Cowie B etal. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011 (Aug 13); 378 (9791): 571-83.
17. Szabo E, Paska C, Kaposi NP, Schaff Z, Kiss A. Similarities and differences in hepatitis B and C virus induced hepatocarcinogenesis. Pathol Oncol Res 2004; 10 (1): 5-11.
18. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006 (Jun 15); 118 (12): 3030-44.
19. McClune AC, Tong MJ. Chronic hepatitis B and hepatocellular carcinoma. Clin Liver Dis 2010 (Aug); 14 (3): 461-76.
20. Alter MJ. HCV routes of transmission: what goes around comes around. Semin Liver Dis 2011 (Nov); 31 (4): 340-6.
21. Lavanchy D. The global burden of hepatitis C. Liver Int 2009 (Jan); 29 (Suppl 1): 74-81.
22. Yamashita T, Honda M, Kaneko S. Molecular mechanisms of hepatocarcinogenesis in chronic hepatitis C virus infection. J Gastroenterol Hepatol 2011 (Jun); 26 (6): 960-4.
23. McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis 2011 (May); 15 (2): 223-43.
24. But DY, Lai CL, Yuen MF. Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol 2008 (Mar 21); 14 (11): 1652-6.
25. Donato F, Tagger A, Gelatti U etal. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002 (Feb 15); 155 (4): 323-31.
26. Hebbard L, George J. Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2011 (Jan); 8 (1): 35-44.
27. Petta S, Camma C, Di Marco V etal. Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. Liver Int 2011 (Apr); 31 (4): 507-15.
28. Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol 2011 (Sep); 26 (9): 1361-7.
29. Na TY, Shin YK, Roh KJ etal. Liver X receptor mediates hepatitis B virus X protein-induced lipogenesis in hepatitis B virus-associated hepatocellular carcinoma. Hepatology 2009 (Apr); 49 (4): 1122-31.
30. Ha HL, Yu DY. HBx-induced reactive oxygen species activates hepatocellular carcinogenesis via dysregulation of PTEN/Akt pathway. World J Gastroenterol 2010 (Oct 21); 16 (39): 4932-7.
31. Kim KH, Shin HJ, Kim K etal. Hepatitis B Virus X Protein Induces Hepatic Steatosis Via Transcriptional Activation of SREBP1 and PPARgamma. Gastroenterology 2007 (May); 132 (5): 1955-67.
32. Kurosaki M, Hosokawa T, Matsunaga K etal. Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy. Hepatol Res 2010 (Sep); 40 (9): 870-7.
33. Ohata K, Hamasaki K, Toriyama K etal. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003 (Jun 15); 97 (12): 3036-43.
34. Koike K. Steatosis, liver injury, and hepatocarcinogenesis in hepatitis C viral infection. J Gastroenterol 2009; 44 (Suppl 19): 82-8.
35. McGivern DR, Lemon SM. Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene 2011 (Apr 28); 30 (17): 1969-83.
36. Lerat H, Honda M, Beard MR etal. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 2002 (Feb); 122 (2): 352-65.
37. Majumder M, Steele R, Ghosh AK etal. Expression of hepatitis C virus non-structural 5A protein in the liver of transgenic mice. FEBS Lett 2003 (Dec 18); 555 (3): 528-32.
38. Wang AG, Lee DS, Moon HB etal. Non-structural 5A protein of hepatitis C virus induces a range of liver pathology in transgenic mice. J Pathol 2009 (Oct); 219 (2): 253-62.
39. Ye B, Shen J, Xu Y. [Etiologic study on the relationship between HBV, HCV and HCC]. Zhonghua Liu Xing Bing Xue Za Zhi 1994 (Jun); 15 (3): 131-4.
40. Benvegnu L, Fattovich G, Noventa F etal. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer 1994 (Nov 1); 74 (9): 2442-8.
41. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998 (Jan 30); 75 (3): 347-54.
42. Wang Q, Zhang WY, Ye LH, Zhang XD. A mutant of HBx (HBxDelta127) promotes hepatoma cell growth via sterol regulatory element binding protein 1c involving 5-lipoxygenase. Acta Pharmacol Sin 2010 (Mar); 31 (3): 367-74.
43. Kim JY, Song EH, Lee HJ etal. HBx-induced hepatic steatosis and apoptosis are regulated by TNFR1- and NF-kappaB-dependent pathways. J Mol Biol 2010 (Apr 9); 397 (4): 917-31.
44. Wu JM, Skill NJ, Maluccio MA. Evidence of aberrant lipid metabolism in hepatitis C and hepatocellular carcinoma. HPB (Oxford) 2010 (Nov); 12 (9): 625-36.
45. Koike K. Hepatitis C virus contributes to hepatocarcinogenesis by modulating metabolic and intracellular signaling pathways. J Gastroenterol Hepatol 2007 (Jun); 22 (Suppl 1): S108-S111.
46. Joyce MA, Walters KA, Lamb SE etal. HCV induces oxidative and ER stress, and sensitizes infected cells to apoptosis in SCID/Alb-uPA mice. PLoS Pathog 2009 (Feb); 5 (2): e1000291.
47. Moriya K, Fujie H, Shintani Y etal. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998 (Sep); 4 (9): 1065-7.
48. Koike K, Moriya K, Ishibashi K etal. Expression of hepatitis C virus envelope proteins in transgenic mice. J Gen Virol 1995 (Dec); 76 (Pt 12): 3031-8.
49. Lerat H, Kammoun HL, Hainault I etal. Hepatitis C virus proteins induce lipogenesis and defective triglyceride secretion in transgenic mice. J Biol Chem 2009 (Nov 27); 284 (48): 33466-74.
50. Wang AG, Moon HB, Kim JM, Hwang SB, Yu DY, Lee DS. Expression of hepatitis C virus nonstructural 4B in transgenic mice. Exp Mol Med 2006 (Jun 30); 38 (3): 241-6.
51. Waris G, Felmlee DJ, Negro F, Siddiqui A. Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress. J Virol 2007 (Aug); 81 (15): 8122-30.
52. Park CY, Jun HJ, Wakita T, Cheong JH, Hwang SB. Hepatitis C virus nonstructural 4B protein modulates sterol regulatory element-binding protein signaling via the AKT pathway. J Biol Chem 2009 (Apr 3); 284 (14): 9237-46.
53. Hourioux C, Patient R, Morin A etal. The genotype 3-specific hepatitis C virus core protein residue phenylalanine 164 increases steatosis in an in vitro cellular model. Gut 2007 (Sep); 56 (9): 1302-8.
54. Jackel-Cram C, Babiuk LA, Liu Q. Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core. J Hepatol 2007 (Jun); 46 (6): 999-1008.
55. Jackel-Cram C, Qiao L, Xiang Z etal. Hepatitis C virus genotype-3a core protein enhances sterol regulatory element-binding protein-1 activity through the phosphoinositide 3-kinase-Akt-2 pathway. J Gen Virol 2010 (Jun); 91 (Pt 6): 1388-95.
56. Kim KH, Hong SP, Kim K, Park MJ, Kim KJ, Cheong J. HCV core protein induces hepatic lipid accumulation by activating SREBP1 and PPARgamma. Biochem Biophys Res Commun 2007 (Apr 20); 355 (4): 883-8.
57. Tanaka N, Moriya K, Kiyosawa K, Koike K, Gonzalez FJ, Aoyama T. PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J Clin Invest 2008 (Feb); 118 (2): 683-94.
58. Oem JK, Jackel-Cram C, Li YP etal. Activation of sterol regulatory element-binding protein 1c and fatty acid synthase transcription by hepatitis C virus non-structural protein 2. J Gen Virol 2008 (May); 89 (Pt 5): 1225-30.
59. Xiang Z, Qiao L, Zhou Y, Babiuk LA, Liu Q. Hepatitis C virus nonstructural protein-5A activates sterol regulatory element-binding protein-1c through transcription factor Sp1. Biochem Biophys Res Commun 2010 (Nov 19); 402 (3): 549-53.
60. Kim K, Kim KH, Ha E, Park JY, Sakamoto N, Cheong J. Hepatitis C virus NS5A protein increases hepatic lipid accumulation via induction of activation and expression of PPARgamma. FEBS Lett 2009 (Sep 3); 583 (17): 2720-6.
61. Keasler VV, Lerat H, Madden CR etal. Increased liver pathology in hepatitis C virus transgenic mice expressing the hepatitis B virus X protein. Virology 2006 (Apr 10); 347 (2): 466-75.
62. Jung EY, Kang HK, Chang J, Yu DY, Jang KL. Cooperative transformation of murine fibroblast NIH3T3 cells by hepatitis C virus core protein and hepatitis B virus X protein. Virus Res 2003 (Aug); 94 (2): 79-84.
63. Ma Z, Shen QH, Chen GM, Zhang DZ. Biological impact of hepatitis B virus X-hepatitis C virus core fusion gene on human hepatocytes. World J Gastroenterol 2008 (Sep 21); 14 (35): 5412-18.
64. Han HJ, Jung EY, Lee WJ, Jang KL. Cooperative repression of cyclin-dependent kinase inhibitor p21 gene expression by hepatitis B virus X protein and hepatitis C virus core protein. FEBS Lett 2002 (May 8); 518 (1-3): 169-72.
65. Liu H, Liu JY, Wu X, Zhang JT. Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker. Int J Biochem Mol Biol 2010 (Jul 18); 1 (1): 69-89.
66. Flavin R, Peluso S, Nguyen PL, Loda M. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol 2010 (Apr); 6 (4): 551-62.
67. Pyper SR, Viswakarma N, Yu S, Reddy JK. PPARalpha: energy combustion, hypolipidemia, inflammation and cancer. Nucl Recept Signal 2010; 8: e002.
68. Krycer JR, Sharpe LJ, Luu W, Brown AJ. The Akt-SREBP nexus: cell signaling meets lipid metabolism. Trends Endocrinol Metab 2010 (May); 21 (5): 268-76.
69. Porstmann T, Griffiths B, Chung YL etal. PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene 2005 (Sep 29); 24 (43): 6465-81.
70. Garcia-Echeverria C, Sellers WR. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 2008 (Sep 18); 27 (41): 5511-26.
71. Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 2008 (May); 8 (3): 187-98.
72. Tokunaga E, Oki E, Egashira A etal. Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets 2008 (Feb); 8 (1): 27-36.
73. Maira SM, Voliva C, Garcia-Echeverria C. Class IA phosphatidylinositol 3-kinase: from their biologic implication in human cancers to drug discovery. Expert Opin Ther Targets 2008 (Feb); 12 (2): 223-38.
74. Ferre P, Foufelle F. Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes Metab 2010 (Oct); 12 (Suppl 2): 83-92.
75. Dara L, Ji C, Kaplowitz N. The contribution of endoplasmic reticulum stress to liver diseases. Hepatology 2011 (May); 53 (5): 1752-63.
76. Zhang K, Wang S, Malhotra J etal. The unfolded protein response transducer IRE1alpha prevents ER stress-induced hepatic steatosis. EMBO J 2011 (Apr 6); 30 (7): 1357-75.
77. Malhi H, Kaufman RJ. Endoplasmic reticulum stress in liver disease. J Hepatol 2011 (Apr); 54 (4): 795-809.
78. Basseri S, Austin RC. ER stress and lipogenesis: a slippery slope toward hepatic steatosis. Dev Cell 2008 (Dec); 15 (6): 795-6.
79. Lee JN, Ye J. Proteolytic activation of sterol regulatory element-binding protein induced by cellular stress through depletion of Insig-1. J Biol Chem 2004 (Oct 22); 279 (43): 45257-65.
80. Colgan SM, Tang D, Werstuck GH, Austin RC. Endoplasmic reticulum stress causes the activation of sterol regulatory element binding protein-2. Int J Biochem Cell Biol 2007; 39 (10): 1843-51.
81. Sanderson LM, Degenhardt T, Koppen A etal. Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) but not PPARalpha serves as a plasma free fatty acid sensor in liver. Mol Cell Biol 2009 (Dec); 29 (23): 6257-67.
82. Shan W, Nicol CJ, Ito S etal. Peroxisome proliferator-activated receptor-beta/delta protects against chemically induced liver toxicity in mice. Hepatology 2008 (Jan); 47 (1): 225-35.
83. Shan W, Palkar PS, Murray IA etal. Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression. Toxicol Sci 2008 (Oct); 105 (2): 418-28.